Current and Future Directions in GBM Management

Current and Future Directions in GBM Management

Incorporating New Strategies

Not a member of My prIME? Join now for instant access.

The Society for Neuro-Oncology has reviewed and approved this symposium as appropriate for presentation as an Industry Supported Symposium. The symposium constitutes the content and views of the sponsor and is not part of the official SNO Annual Meeting program.

Meeting Overview

Learn about optimal treatment approaches for patients with newly diagnosed and recurrent glioblastoma (GBM) at this interactive satellite symposium. A variety of therapeutic strategies will be discussed, with a focus on local therapy and immunotherapy. Attendees will have the opportunity to interact with the expert faculty throughout the symposium.

This is a prIME Oncology satellite symposium held in conjunction with the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO).

Date and Location

Friday, November 17, 2017
12:15 PM – 1.15 PM

Yerba Buena 13-15
San Francisco Marriott Marquis
780 Mission Street
San Francisco, California 94103



Friday, November 17, 2017
12:15 PM – 1.15 PM



San Francisco, California, United States



1.0 AMA PRA Category 1 Credit

12.15 PM Welcome and introduction
Maciej Mrugala, MD, PhD, MPH
12.20 PM A new look at local therapy in GBM
Rimas Lukas, MD
12.40 PM The impact of immunotherapy in GBM: Now and in the near term
David Reardon, MD
1.00 PM Question and answer panel
1.05 PM Clinical vignettes revisited and prIME Points™
Maciej Mrugala, MD, PhD, MPH
1.15 PM Adjourn


  • Maciej Mrugala, MD, PhD, MPHMayo Clinic
    Phoenix, Arizona, United States
  • Faculty

  • Rimas Lukas, MDNorthwestern University
    Feinberg School of Medicine
    Chicago, Illinois, United States
  • David Reardon, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States

This educational activity is specifically designed to meet the needs of neuro-oncologists, medical oncologists, radiation oncologists, and other health care professionals providing care to patients with glioblastoma.

After successful completion of this educational activity, participants should be able to:

  • Select optimal therapy for patients diagnosed with GBM
  • Assess safety and efficacy data for new and emerging therapies for GBM

This educational activity is supported by a grant from Novocure.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.

Sunshine Act

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.